Galectin Therapeutics
GALT
58 hedge funds and large institutions have $9.08M invested in Galectin Therapeutics in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 15 closing their positions.
6% less funds holding
Funds holding: 62 → 58 (-4)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
33% less capital invested
Capital invested by funds: $13.6M → $9.08M (-$4.56M)
97% less call options, than puts
Call options by funds: $7K | Put options by funds: $224K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$473K |
| 2 |
US Bancorp
Minneapolis,
Minnesota
|
+$274K |
| 3 |
BCCM
Blue Clay Capital Management
Minneapolis,
Minnesota
|
+$225K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$202K |
| 5 |
Millennium Management
New York
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.39M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$739K |
| 3 |
State Street
Boston,
Massachusetts
|
-$581K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$348K |
| 5 |
Bank of New York Mellon
New York
|
-$155K |
GALT Hedge Fund Activity: Q2 2015 in Review
58 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2015, worth a combined $9.08M — down 33% from $13.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of GALT and 12 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was Susquehanna International Group, adding an estimated $473K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.39M.
- 58 institutional investors held Galectin Therapeutics (GALT) as of Q2 2015, down from 62 in Q1 2015.
- Funds reported $9.08M of Galectin Therapeutics stock for Q2 2015, down 33% quarter-over-quarter.
- 12 funds opened new Galectin Therapeutics positions in Q2 2015 and 15 closed out, a net change of -3 holders.
- The largest Galectin Therapeutics buyer in Q2 2015 was Susquehanna International Group, an estimated $473K added.
- The largest Galectin Therapeutics seller in Q2 2015 was BlackRock Fund Advisors, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2015.